Table 3 List of IDeAl added aspects, explanation in brackets
adaptive combination | |
adaptive graph-based multiple | |
adaptive LASSO | |
adaptive strategy | |
adjusted significance level | |
assessment of randomisation procedures | |
Bayesian decision theory | |
biased corrected test (likelihood ratio test) | |
biasing policy | |
BIC criterion | |
blocked ANOVA | |
bootstrap (constrained parametric bootstrap procedure) | |
causal inference | |
CorrMixed | |
decision theoretic aspect (Bayesian decision theoretic) | |
dOFV (delta objective function values) | |
dose-response | |
EffectTreat | |
ERDO (evaluation of randomisation procedures for design optimisation) | |
similarity of dose response | |
FDR (false discovery rate) | |
first-in-human | |
Fisher information matrix | |
SLOPE (group SLOPE, geneSLOPE) | |
k-means | |
linked assessment criterion | |
many-to-one | |
maximum likelihood estimation | |
MC-AGQ | |
MC-HMC | |
MCPMod (closed MCPMod) | |
confidence bands for difference of curves | |
meta-analysis | |
meta-analytic paradigma | |
mixed effects model | |
MIXFIM | |
model averaging | |
model selection | |
monte-carlo | |
stochastic simulation | |
non-parametric | |
open-label | |
optimal-design (compound D-optimality criterion) | |
parametric power estimation | |
permutation test | |
PESEL (penalized semi-integrated likelihood method) | |
pharmacometrics | |
prior information | |
randomisation based inference | |
randomizeR | |
real world data | |
Robustness | |
SIR (sampling importance resampling) | |
scepticism factor (scepticism) | |
selection bias | |
sequential analysis | |
Simulation | |
SPF (surrogate predictive function) | |
stratification | |
personalised medicine | |
SURROGATE | |
TestingSimilarity | |
threshold-crossing | |
time trend bias | |
two-stage adaptive design | |
type-I-error probability | |
intersection-union principle |